Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Kidney Disease
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Chronic Kidney Disease?
Research shows that transcutaneous auricular vagus nerve stimulation (taVNS) can have beneficial effects on heart rate and reduce inflammation, which might be helpful for conditions like chronic kidney disease. Additionally, taVNS has been shown to stabilize heart rhythms and reduce stress on the heart, suggesting potential benefits for kidney health.12345
Is transcutaneous auricular vagus nerve stimulation (taVNS) safe for humans?
How is the treatment Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) unique for chronic kidney disease?
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) is unique because it uses low-intensity electrical currents applied to the ear to stimulate the vagus nerve, which is different from traditional treatments that might involve medication or dialysis. This non-invasive approach aims to leverage the nerve's role in regulating bodily functions, potentially offering anti-inflammatory benefits without the need for drugs.123510
What is the purpose of this trial?
30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.
Research Team
Qandeel Soomro, MD
Principal Investigator
NYU Langone Health
Eligibility Criteria
This trial is for individuals with chronic kidney disease stages 3-5. It's designed to see if a non-invasive nerve stimulation technique can help with nervous system issues related to their condition.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either sham or active taVNS for two weeks, with daily 15-minute sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator